Lilly China is the first to enter the 1 drug network online diabetes management platform

May 8, 2020, Lilly China and 1 Pharmaceutical Network jointly announced that they will continue to deepen cooperation in the field of diabetes through technologies such as Internet hospitals, big data and artificial intelligence. Lilly China will rely on 1 drug network of online diagnosis and treatment, electronic prescriptions, user insights, intelligent supply chain and other Internet technology service capabilities, combined with their deep advantages in the field of diabetes, to help diabetic patients to create a comprehensive diabetes management platform, including disease management, disease education and patient support programs, to enrich the accumulation of knowledge on chronic disease management, better help diabetics home management.The diabetic management platform, which is equipped with an Internet hospital under the 1 pharmaceutical network, will provide a one-stop "medical and pharmaceutical" service that allows patients to communicate online with professional doctors and provide personalized service and delivery of medicines. The hundreds of specialists gathered on the platform can provide professional consultation for patients and realize the dynamic connection between patients and doctors outside the hospital, which can not only facilitate patient management by doctors, but also alleviate the shortage of resources offline. In addition, the platform will establish a comprehensive electronic health archive, achieve information connectivity, help doctors improve the efficiency of diagnosis and treatment, and improve patient compliance through systematic CRM.Lilly China, as the first multinational pharmaceutical company to enter the platform, will give full play to the expertise in the field of diabetes management, effectively integrate drugs, smart devices, big data, artificial intelligence, patient services and other multi-dimensional advantages, integrate advanced technology into all aspects of diabetes management, with the power of "Internet Plus" to further optimize disease management and enhance the drug treatment experience and self-management awareness of diabetics. Lilly China will provide 1 pharmaceutical network with access to innovative drugs in the field of diabetes, thereby helping the platform to further improve patient access to medicines. Lilly China will also provide qualified diabetics with a variety of patient management and welfare programs, including Lilly Excellent (R) and Easy Companion, with the aim of providing personalized diabetes education and health management services for diabetics. In addition, with its deep experience in the field of diabetes, Lilly China will provide professional disease education for patients on this platform, so that more diabetics correctly understand the disease and scientifically control sugar.1 The long-term accumulation of pharmaceutical network in the field of Internet medicine and health, especially in the online operation of diabetics, has laid a solid foundation for the construction of patient management platform. With the support of 1 drug network Internet technology, the platform patients can continue online, obtain medical advice and programs provided by professional doctors, purchase medicines online, and obtain professional drug guidance and post-diagnosis services. Through the independently developed CRM system, Drug Network 1 will also provide drug alert services for platform patients, as well as a variety of relevant information in the field of diabetes, including new drugs, new therapies, etc. The system has played a significant role in significantly improving the drug compliance of diabetic patients, with a natural renewal rate of 39% for diabetics in 2019 and 67% for diabetics with the help of CRM system management.Regarding the cooperation between Lilly China and 1 Pharmaceutical Network in the management of diabetic patients, Mr. Ji Liwen, President and General Manager of Lilly China, commented, "The model of Internet plus medical care has gradually been widely recognized by the government, and Lilly China is also working with a number of third-party platforms, including Internet hospitals, to actively explore innovative business models and channels." The platform for diabetics, which is based on 1 drug network, is a new attempt by Lilly China to develop diabetes management and online disease education through Internet hospitals. Not only that, Lilly China's various types of diabetes care and welfare programs, will also improve drug access at the same time to help the majority of diabetics to achieve scientific and effective self-management, and ultimately achieve treatment goals. Dr., co-founder and executive chairman of the China Diabetes 1 Drug Network, said it was important to help this large group manage its health effectively, with hundreds of millions of people with diabetes in China. 1 Pharmaceutical Network hopes and Lilly China will use its resources and advantages in their respective fields to jointly explore an efficient diabetes management model, deeply cultivate this segmented but huge audience area, and work together to create a one-stop management platform centered on diabetics, with technology as a tool to break through time and geographical constraints, to facilitate doctors and patients, and combine Lilly China's expertise in the field of diabetes, continuous precision and customized education for patients, from diet, exercise, medicine to give patients personalized management and treatment programs, and continuously improve the self-management capacity of diabetic patients, so as to further improve the health of patients, to help "Healthy China 2030" construction.
(1
drug network
)